Press Releases

All

March 10, 2016

ASPYRIAN THERAPEUTICS INC. CLOSES A $40M SERIES B FINANCING TO ADVANCE THE PRECISION TARGETED CANCER THERAPY, RM-1929, TO LATE STAGE CLINICAL DEVELOPMENT IN RECURRENT HEAD AND NECK CANCER AND OTHER CANCER AREAS.

July 27, 2015

ASPYRIAN THERAPEUTICS INC. CLOSES $4.25M SERIES A EXTENSION FINANCING TO SUPPORT THE EXECUTION OF PHASE 1 CLINICAL STUDIES OF THE PRECISION TARGETED CANCER THERAPY, RM-1929, TO TREAT LATE-STAGE RECURRENT HEAD AND NECK CANCERS

May 12, 2015

ASPYRIAN THERAPEUTICS INC. ANNOUNCES FDA ACCEPTANCE INVESTIGATIONAL NEW DRUG APPLICATION FOR RM-1929 A FIRST-IN-CLASS, PRECISION-TARGETED THERAPY FOR CANCER

« Previous 1 … 13 14 15

Year Archive

2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Related Content

About Us

About Us
Letter from Our CEO
Leadership
Location

About

About
Letter from Our CEO
Leadership
Location

Pipeline

Pipeline
Expanded Access Program

Pipeline

Pipeline
Expanded Access Program

News

News
Press Releases
Rakuten Medical Stories
Press Kit

News

News
Press Releases
Rakuten Medical Stories
Press Kit

Contact

Privacy Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

We use cookies to enhance user experience and to analyze performance and website traffic. View our Privacy Policy for more details.

Cookie Settings Accept All Cookies

Privacy & Cookies Policy

Privacy Overview

We use cookies to enhance user experience and to analyze performance and website traffic. View our Privacy Policy for more details.
Do not sell my personal information

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages. Keeping this cookie enabled helps us to improve our website.

SAVE & ACCEPT